Abstract
Background: Irritable bowel syndrome (IBS) is a complex syndrome that is difficult to manage. Here we present the evidence supporting medication treatments for specific IBS symptoms, discuss evidence-based management of IBS with medications including dose regimens and adverse effects and review progress on research for new IBS treatments. Summary: Currently, there is evidence to support improvements in specific IBS symptoms following treatment with loperamide, psyllium, bran, lubiprostone, linaclotide, amitriptyline, trimipramine, desipramine, citalopram, fluoxetine, paroxetine, dicyclomine, peppermint oil, rifaximin, ketotifen, pregabalin, gabapentin and octreotide and there are many new medications being investigated for the treatment of IBS. Key Message: Of the medications with demonstrated improvements for IBS symptoms, rifaximin, lubiprostone, linaclotide, fiber supplementation and peppermint oil have the most reliable evidence supporting their use for the treatment of IBS. Onset of efficacy for the various medications has been noted to be as early as 6 days after initiation; however, the efficacy of most medications was not assessed prospectively at predefined periods. Additional studies of currently available and new medications are ongoing and are needed to better define their place in therapy and expand therapeutic options for the treatment of IBS. The most promising new medications for IBS include a variety of novel pharmacologic approaches, most notably the dual μ-opioid receptor agonist and δ-opioid antagonist, JNJ-27018966.
Journal Section:
Review
References
1.
Hungin APS, Chang GR, Locke GR, Dennis EH, Bargout V: Irritable bowel syndrome in the United States: prevalence, symptom patterns and impact. Alimentary Pharmacol Ther 2005;21:1365-1375.
[PubMed]
2.
Brandt LJ, Bjorkman D, Fennerty B, Locke GR, Olden K, Peterson W, Quigley E, Schoenfeld P, Schuster M, Talley N: Systematic review on the management of irritable bowel syndrome in North America. Am J Gastroenterol 2002;97:S7-S26
[PubMed]
3.
Brandt LJ, Chey WD, Foxx-Orenstein AE, Quigley EMM, Schiller LR, Schoenfeld PS, Spiegel BM, Talley NJ, Moayyedi P: An evidence-based systematic review on the management of irritable bowel syndrome. Am J Gastroenterol 2009;104:S8-S35.
[PubMed]
4.
Lubiprostone. Package Insert. Takeda Pharmaceuticals America, Inc., April 2013. Available at: http://www.accessdata.fda.gov/drugs- atfda_docs/label/2013/021908s011lbl.pdf. Accessed June 4, 2014.
5.
Johanson JF, Drossman DA, Panas R, Wahle A, Ueno R: Clinical trial: phase 2 study of lubiprostone for irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2008;27:685-696.
[PubMed]
6.
Johnston JM, Lurtz CB, MacDougall JE, Lavins BJ, Currie MG, Fitch DA, O'Dea C, Baird M, Lembo AJ: Linaclotide improves abdominal pain and bowel habits in a phase IIb study of patients with irritable bowel syndrome with constipation. Gastroenterol 2010;139:1877-1886.
[PubMed]
7.
Quigley EMM, Tack J, Chey WD, Rao SS, Fortea J, Falques M, Diaz C, Shiff SJ, Currie MG, Johnston JM: Randomized clinical trials: linaclotide phase 3 studies in IBS-C-a prespecified further analysis based on European Medicines Agency-specified endpoints. Aliment Pharmacol Ther 2013;37:49-61.
[PubMed]
8.
Rao SR, Lembo AJ, Shiff SJ, Lavins BJ, Currie MG, Jia XD, Shi K, MacDougall JE, Shao JZ, Eng P, Fox SM, Schneider HA, Kurtz CB, Johnston JM: A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation. Am J Gastroenterol 2012;107:1714-1724.
[PubMed]
9.
Chey WD, Lembo AJ, Lavins BJ, Shiff SJ, Kurtz CB, Currie MG, MacDougall JE, Jia XD, Shao JZ, Fitch DA, Baird MJ, Schneider HA, Johnston JM: Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety. Am J Gastroenterol 2012;107:1702-1712.
[PubMed]
10.
Lembo A, Zakko SF, Ferreira NL, Ringel Y, Bortey E, Courtney K, Corsi E, Forbes WP, Pimentel M: Rifaximin for the treatment of diarrhea associated irritable bowel syndrome: short-term treatment leading to long-term sustained response (abstract T1390). Gastroenterology 2008;134(suppl 1):A545.
11.
Rifaximin. Package Insert. Salix Pharmaceuticals, Inc., March 2013. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021361s013lbl.pdf. Accessed June 4, 2014.
12.
Food and Drug Administration. Xifaxan (rifaximin) tablets, 550 μg NDA 21-361: Briefing document for gastrointestinal drugs advisory committee meeting 16 November 2011. Available at http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/gastrointestinaldrugsadvisorycommittee/ucm279646.pdf. Accessed September 27, 2013.
13.
Jalihal A, Kurian G: Ispaghula therapy in irritable bowel syndrome: improvement in overall well-being is related to reduction in bowel dissatisfaction. J Gastroenterol Hepatol 1990;5:507-513.
[PubMed]
14.
Bijkerk CJ, de Wit NJ, Muris JW, Whorwell PJ, Knottnerus JA, Hoes AW: Soluble or insoluble fibre in irritable bowel syndrome in primary care? Randomised placebo controlled trial. BMJ 2009;339:b3154.
[PubMed]
15.
Prior A, Whorwell P: Double blind study of ispaghula in irritable bowel syndrome. Gut 1987;28:1510-1513.
[PubMed]
16.
Arthurs Y, Fielding JF: Double blind trial of ispaghula/poloxamer in the irritable bowel syndrome. Irish Med J 1983;76:253.
[PubMed]
17.
Ritchie JA, Truelove SC: Treatment of irritable bowel syndrome with lorazepam, hyoscine butylbromide, and ispaghula husk. Br Med J 1979;i:376-378.
[PubMed]
18.
Longstreth GF, Fox DD, Youkeles L, Forsythe AB, Wolochow DA: Psyllium therapy in the irritable bowel syndrome. Ann Intern Med 1981;95:53-56.
[PubMed]
19.
Liu JH, Chen GH, Yeh HZ, Huang CK, Poon SK: Enteric-coated peppermint-oil capsules in the treatment of irritable bowel syndrome: a prospective, randomized trial. J Gastroenterol 1997;2:765-768.
[PubMed]
20.
Alam MS, Roy PK, Miah AR, Mollick SH, Han MR, Mahmud MC, Khatun S: Efficacy of peppermint oil in diarrhea predominant IBS - a double-blind randomized placebo-controlled study. Mymensingh Med 2013;22:27-30.
[PubMed]
21.
Cappello G, Spezzaferro M, Grossi L, Manzoli L, Marzio L: Peppermint oil (Mintoil) in the treatment of irritable bowel syndrome: a prospective double-blind placebo controlled randomized trial. Dig Liver Dis 2007;39:530-536.
[PubMed]
22.
Page JG, Dirnberger GM: Treatment of the irritable bowel syndrome with Bentyl (dicyclomine hydrochloride). J Clin Gastroenterol 1981;3:153-156.
[PubMed]
23.
Cann PA, Read NW, Holdsworth CD, Barends D: Role of loperamide and placebo in management of irritable bowel syndrome (IBS). Dig Dis Sci 1984;29:239-247.
[PubMed]
24.
Efskind PS, Bernklev T, Vatn MH: A double-blind placebo-controlled trial with loperamide in irritable bowel syndrome. Scand J Gastroenterol 1996;31:463-468.
[PubMed]
25.
Lavo B, Stenstam M, Nielsen AL: Loperamide in treatment of irritable bowel syndrome - a double-blind placebo-controlled study. Scand J Gastroenterol 1987;130:S77-S80.
[PubMed]
26.
Loperamide. Package Insert. Janssen Pharmaceutica Inc., July 1998. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2005/017694s050lbl.pdf. Accessed June 4, 2014.
27.
Tack J, Broekaert D, Fischler B, Van Oudenhove L, Gevers AM, Janssens J: A controlled crossover study of the selective serotonin reuptake inhibitor citalopram in irritable bowel syndrome. Gut 2006;55:1095-1103.
[PubMed]
28.
Vahedi H, Merat S, Rashidioon A, Ghoddoosi A, Malekzadeh R: The effect of fluoxetine in patients with pain and constipation-predominant irritable bowel syndrome: a double-blind randomized-controlled study. Aliment Pharmacol Ther 2005;22:381-385.
[PubMed]
29.
Masand PS, Pae CU, Krulewicz S, Peindl K, Mannelli P, Varia IM, Patkar AA: A double-blind, randomized, placebo-controlled trial of paroxetine controlled-release in irritable bowel syndrome. Psychosomatics 1990;50:78-86.
[PubMed]
30.
Vahedi H, Merat S, Momtahen S, Kazzazi S, Ghaffari N, Olfati G, Malekzadeh R: Clinical trial: the effect of amitriptyline in patients with diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2008;27:678-684.
[PubMed]
31.
Rajagopalan M, Kurian G, John J: Symptom relief with amitriptyline in the irritable bowel syndrome. J Gastroenterol Hepatol 1998;13:738-741.
[PubMed]
32.
Bahar RJ, Collins BS, Steinmetz B, Ament ME: Double-blind, placebo-controlled trial of amitriptyline for the treatment of irritable bowel syndrome in adolescents. J Pediatr 2008;152:685-689.
[PubMed]
33.
Myren J, Groth H, Larssen SE, Larsen S: The effect of trimipramine in patients with the irritable bowel syndrome. Scand J Gastroenterol 1982;17:871-875.
[PubMed]
34.
Myren J, Lovland B, Larssen S-E, Larsen S: A double-blind study of the effect of trimipramine in patients with irritable bowel syndrome. Scand J Gastroenterol 1984;19:835-843.
[PubMed]
35.
Greenbaum DS, Mayle JE, Vanegeren LE, Jerome JA, Mayor JW, Greenbaum RB, Matson RW, Stein GE, Dean HA, Halvorsen NA: Effects of desipramine on irritable bowel syndrome compared with atropine and placebo. Dig Dis Sci 1987;32:257-266.
[PubMed]
36.
Vij JG, Jiloha RG, Kumar N: Effect of antidepressant drug (doxepin) on irritable bowel syndrome patients. Ind J Psychiatry 1991;33, 243-246.
37.
Kooker TK, Braak B, Koopman KE, Welting O, Wouters MM, van der Heide S, Schemann M, Bischoff SC, van den Wijngaard RM, Boeckxstaens GE: The mast cell stabilizer ketotifen decreases visceral hypersensitivity and improves intestinal symptoms in patients with irritable bowel syndrome. Gut 2010;59:1213-1221.
[PubMed]
38.
Lee KJ, Kim JH, Cho SW: Gabapentin reduces rectal mechanosensitivity and increases compliance in patients with diarrhea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2005;22:981-988.
[PubMed]
39.
Houghton LA, Fell C, Whorwell PJ, Jones I, Sudworth DP, Gale JD: Effect of a second-generation α2δ ligand (pregabalin) on visceral sensation in hypersensitive patients with irritable bowel syndrome. Gut 2007;56:1218-1225.
[PubMed]
40.
Klooker TK, Kuiken SD, Lei A, Boeckxstaens GE: Effect of long-term treatment with octreotide on rectal sensitivity in patients with non-constipated irritable bowel syndrome. Aliment Pharmacol Ther 2007;26:605-615.
[PubMed]
41.
Octreotide. Package Insert. Novartis Pharmaceuticals Corporation March 2012. Available at: http://www.accessdata.fda.gov/drugs- atfda_docs/label/2012/019667s061lbl.pdf. Accessed June 4, 2014.
42.
Camilleri M, Kim DY, McKinzie S, Kim HJ, Thomforde GM, Burton DD, Low PA, Zinsmeister AR: A randomized, controlled exploratory study of clonidine in diarrhea-predominant irritable bowel syndrome. Clin Gastroenterol Hepatol 2003;1:111-121.
[PubMed]
43.
Clinical trials.gov: Find Studies. Available at clinicaltrials.gov. Accessed November 19, 2013.
44.
Lazard Capital Markets Annual Healthcare Conference. Furiex Pharmaceuticals. Available at http://files.shareholder.com/downloads/ABEA-4H9PM3/0x0x550458/a546b8d0-d614-4136-9514-3c960c74649f/Lazard%20Capital%20Markets%20Annual%20Healthcare%20Conference%20Presentation. Accessed November 11, 2013.
45.
Hellstrom PM, Hein J, Bytzer P, Bjornsson E, Kristensen J, Schambye H: Clinical trial: the glucagon-like peptide-1 analogue ROSE-010 for management of acute pain in patients with irritable bowel syndrome: a randomized, placebo-controlled, double-blind study. Aliment Pharmacol Ther 2009;29:198-206.
[PubMed]
46.
Tack JF, Miner PB, Fischer L, Harris MS: Randomised clinical trial: the safety and efficacy of AST-120 in non-constipating irritable bowel syndrome - a double-blind, placebo-controlled study. Aliment Pharmacol Ther 2011;43:868-877.
[PubMed]
47.
Mangel AW, Bornstein JD, Hamm LR, Buda J, Wang J, Irish W, Urso D: Clinical trial: asimadoline in the treatment of patients with irritable bowel syndrome. Aliment Pharmacol Ther 2008;28:239-249.
[PubMed]
48.
Whitehead WE, Palsson OS, Gangarosa L, Turner M, Tucker J: Lubiprostone does not influence visceral pain thresholds in patients with irritable bowel syndrome. Neurogastroenterol Motil 2011;23:944-e400.
[PubMed]
49.
Pimentel M, Sandy P, Mirocha J, Kane SV, Kong Y: The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome. Ann Intern Med 2006;145:557-563.
[PubMed]
50.
Pimental M, Lembo A, Chey WD, Zakko S, Ringel Y, Yu J, Mareya SM, Shaw AL, Bortey E, Forbes WP: Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med 2011;364:22-32.
[PubMed]
51.
Merat S, Khalili S, Mostajabi P, Ghorbani A, Ansari R, Malekzadeh R: The effect of enteric-coated, delayed-release peppermint oil on irritable bowel syndrome. Dig Dis Sci 2010;55:1385-1390.
[PubMed]
52.
Hovdenak N: Loperamide treatment of the irritable bowel syndrome. Scand J Gastroenterol 1987;130:S81-S84.
[PubMed]
53.
Talley NJ, Kellow JE, Boyce P, Tennant C, Huskic S, Jones M: Antidepressant therapy (imipramine and citalopram) for irritable bowel syndrome: a double-blind, randomized, placebo-controlled trial. Dig Dis Sci 2008;53:108-115.
[PubMed]
54.
Heefner JD, Wilder RM, Wilson ID: Irritable colon and depression. Psychosomatics 1978;19:540-547.
[PubMed]
55.
Ladabaum U, Sharabidze A, Levin TR, Zhao WK, Chung E, Bacchetti P, Jin C, Grimes B, Pepin CJ: Citalopram provides little or no benefit in nondepressed patients with irritable bowel syndrome. Clin Gastroenterol Hepatol 2010;8:42-48.
[PubMed]
56.
Kuiken SD, Tytgat GNJ, Boeckxstaens GEE: The selective serotonin reuptake inhibitor fluoxetine does not change rectal sensitivity and symptoms in patients with irritable bowel syndrome: a double-blind, randomized, placebo-controlled study. Clin Gastroenterol Hepatol 2003;1:219-228.
[PubMed]
57.
Forte LR Jr: Uroguanylin and guanylin peptides: pharmacology and experimental therapeutics. Pharmacol Ther 2004;104:137-162.
[PubMed]
58.
Eutamene H, Bradesi S, Larauce M, Theodorou V, Beaufrand C, Ohning G, Fiormonti J, Cohen M, Bryant AP, Kurtz C, Currie MG, Mayer EA, Bueno L: Guanylate cyclase C-mediated antinociceptive effects of linaclotide in rodent models of visceral pain. Neurogastroenterol Motil 2010;22:312-e84.
[PubMed]
59.
Blikslager AT, Moeser AJ, Gookin JL, Jones SL, Odle J: Restoration of barrier function in injured intestinal mucosa. Physiol Rev 2007;87:545-564.
[PubMed]
60.
Hills JM, Aaronson PI: The mechanism of action of peppermint oil on gastrointestinal smooth muscle. Gastroenterology 1991;101:55-65.
[PubMed]
61.
Sohn W, Yee OY, Kwon JG, Park KS, Lim YJ, Kim TH, Jung SW, Kim JI: Tianeptine vs. amitriptyline for the treatment of irritable bowel syndrome with diarrhea: a multicenter, open-label, non-inferiority, randomized controlled study. Neurogastroenterol Motil 2012;24:860-e398.
[PubMed]
62.
Medi-Span. Medi-Span Average WAC Pricing File. Available at http://www.medispan.com/average-wac-pricing-file/. Accessed November 16, 2013.
63.
Bubenik GA: Gastrointestinal melatonin: localization, function, and clinical relevance. Dig Dis Sci 2002;47:2336-2348.
[PubMed]
© 2014 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2014
You do not currently have access to this content.
